{"id":409,"date":"2025-04-15T09:30:00","date_gmt":"2025-04-15T13:30:00","guid":{"rendered":"https:\/\/www.inflation.us\/news\/?p=409"},"modified":"2025-05-08T07:59:28","modified_gmt":"2025-05-08T11:59:28","slug":"hydreight-tsxv-nurs-expands-glp-1-telehealth-suite-with-launch-of-liraglutide-on-vsdhone-platform","status":"publish","type":"post","link":"https:\/\/www.inflation.us\/news\/announcement\/hydreight-tsxv-nurs-expands-glp-1-telehealth-suite-with-launch-of-liraglutide-on-vsdhone-platform\/","title":{"rendered":"Hydreight (TSXV: NURS) Expands GLP-1 Telehealth Suite with Launch of Liraglutide on VSDHOne Platform"},"content":{"rendered":"\n

Huge<\/span> news<\/strong> out from Hydreight Technologies (TSXV: NURS)<\/strong>. This is a rapidly growing<\/strong><\/span> future<\/span> household name company <\/strong>that is set to become<\/span> <\/strong>a leader<\/span> <\/strong>of America’s booming<\/span> telehealth technology space across all<\/span> 50 states!<\/strong><\/span><\/span><\/p>\n\n

RFK Jr. <\/strong>told NIA’s President<\/strong> at Trump’s Inauguration<\/strong> that he is extremely bullish<\/strong><\/span> on telehealth technology<\/strong> and believes it will play the most important <\/strong><\/span>key<\/strong> role<\/strong> to making<\/span> America healthy<\/span> again<\/strong>!<\/span><\/span><\/p>\n\n

Hydreight Technologies Expands<\/span> GLP-1 Telehealth Suite with Launch<\/span> of Liraglutide on VSDHOne Platform<\/span><\/h1>\n\n

Liraglutide Offers<\/span> Long-Term Stability<\/span> and Expands<\/span> Hydreight’s Comprehensive<\/span> GLP-1 Weight Management Portfolio<\/span><\/h2>\n\n

VANCOUVER, British Columbia and LAS VEGAS, April 15, 2025 (GLOBE NEWSWIRE) — Hydreight Technologies Inc.<\/strong> (“Hydreight”or the “Company”) (TSXV: NURS<\/strong>) (OTCQB: HYDTF<\/strong>), a fast-growing<\/span> mobile clinical network<\/strong> and medical platform<\/strong> which enables flexible<\/span> at-home medical services<\/strong> across 50 states<\/strong> in the United States, is pleased to announce<\/strong><\/span> the expansion<\/strong><\/span> of its VSDHOne platform<\/strong> with the launch<\/strong><\/span> of Liraglutide<\/strong>. This addition<\/strong><\/span> marks a strategic<\/strong><\/span> expansion<\/strong><\/span> of Hydreight’s growing<\/span> GLP-1 weight management<\/strong> and wellness offerings<\/strong>, strengthening<\/strong><\/span> its commitment<\/strong> to accessible<\/strong><\/span> and innovative<\/span> solutions<\/strong> through its national<\/span> telehealth network<\/strong>.<\/span><\/p>\n\n

Hydreight’s current GLP-1 offerings now include:<\/strong><\/span><\/p>\n\n

    \n\t
  • Semaglutide<\/strong> (weekly injectable)<\/span>
    \n\t <\/li>\n\t
  • Tirzepatide<\/strong> (dual-action, weekly injectable)<\/span>
    \n\t <\/li>\n\t
  • Liraglutide<\/strong> (newly launched, daily injectable)<\/em><\/span>
    \n\t <\/li>\n\t
  • Sublingual & Buccal GLP-1s<\/strong> (needle-free administration)<\/span><\/li>\n<\/ul>\n\n

    These offerings include a range <\/strong><\/span>of <\/strong><\/span>delivery methods<\/strong> to meet <\/strong><\/span>the diverse needs<\/strong><\/span> of patients<\/strong> and providers<\/strong>—from weekly<\/strong> or daily injectables<\/strong> to sublingual<\/strong> and buccal<\/strong> formats. Sublingual doses are dissolved under the tongue, and buccal is absorbed through the cheek, offering flexibility for those who prefer not to use needles while maintaining consistent dosage options. This variety ensures<\/strong><\/span> tailored<\/strong><\/span>, scalable<\/span> solutions<\/strong> for weight management<\/strong> and metabolic care<\/strong>.<\/span><\/p>\n\n

    A Strategic<\/span> Addition<\/span> for Stability & Choice<\/strong><\/span><\/p>\n\n

    As demand<\/strong><\/span> for GLP-1 medications surges<\/span><\/strong>, Hydreight’s inclusion<\/span><\/strong> of Liraglutide introduces<\/span><\/strong> a stable<\/strong><\/span>, patent-free<\/strong><\/span>, and clinically proven <\/strong><\/span>option<\/strong>—ideal for patients and providers seeking <\/span>consistent<\/span> long-term therapies<\/strong> amid evolving supply and regulatory landscapes. Unlike newer GLP-1 entrants, Liraglutide’s established<\/span> track record<\/strong> and daily dosing format<\/strong> offer<\/span> flexibility<\/span> without compromising<\/span> efficacy<\/strong>.<\/span><\/p>\n\n

    “The launch<\/strong><\/span> of Liraglutide further deepens<\/span> <\/strong>our commitment<\/strong> to expanding access<\/strong><\/span> to proven<\/span> GLP-1 therapies<\/strong>,” said Shane Madden<\/strong>, CEO of Hydreight<\/strong>. “It doesn’t<\/span> replace<\/span><\/strong> anything—it expands<\/strong><\/span> our offering<\/strong>. No <\/strong><\/span>matter<\/strong> how the landscape shifts<\/span><\/strong>, Hydreight<\/strong> users<\/strong> can count on<\/strong><\/span> a complete<\/strong><\/span> and reliable<\/span> GLP-1 portfolio<\/strong>.”<\/span><\/p>\n\n

    Why Liraglutide?<\/strong><\/span><\/p>\n\n

    Liraglutide<\/strong> is a GLP-1 receptor agonis<\/strong>t used in the management of obesity<\/strong> and type 2 diabetes<\/strong>. Delivered via once-daily injection<\/strong>, it offers<\/span> consistent<\/span><\/strong> and clinically proven<\/span> efficacy<\/strong>. Compared to sublingual GLP-1s<\/strong>, which have lower<\/span> bioavailability<\/strong> and shorter<\/span> duration<\/strong> of action<\/strong><\/span>, Liraglutide’s injectable form<\/strong> ensures <\/span>direct<\/span> systemic absorption<\/strong> and predictable<\/strong><\/span>, long-lasting <\/strong><\/span>effects<\/strong>.<\/span><\/p>\n\n

    Comprehensive & Customizable Delivery Options Hydreight’s GLP-1 portfolio now supports multiple<\/span> delivery methods:<\/strong><\/span><\/p>\n\n

      \n\t
    • Injectables: <\/strong>Weekly, biweekly, or daily based on patient needs<\/span>
      \n\t <\/li>\n\t
    • Sublingual: <\/strong>Dissolved under the tongue<\/span>
      \n\t <\/li>\n\t
    • Buccal: <\/strong>Absorbed through the inner cheek<\/span><\/li>\n<\/ul>\n\n

      This mix of injectable, sublingual, and buccal options<\/strong> positions Hydreight<\/strong> as a category leader<\/span><\/strong> in GLP-1 administration versatility<\/span>. <\/strong>It allows medical professionals to provide customized, scalable care while ensuring patient adherence and comfort.<\/span><\/p>\n\n

      Unlocking Access via VSDHOne<\/strong><\/span><\/p>\n\n

      The VSDHOne platform enables a seamless patient journey—from telehealth consultation to prescription and nationwide delivery. It supports medical professionals with flexible tools while ensuring regulatory compliance across all services.<\/span><\/p>\n\n

      “Hydreight isn’t<\/span><\/strong> just a tech stack<\/strong>—we’re a full-service<\/span> medical infrastructure<\/strong>,” added Madden. “With over<\/strong><\/span> 400 licenses sold<\/strong> across<\/strong><\/span> the U.S.<\/strong>, we’re creating<\/strong><\/span> a scalable<\/strong><\/span>, future-ready solution<\/strong><\/span> for wellness<\/strong>, weight loss<\/strong>, and personalized<\/span> healthcare<\/strong>.”<\/span><\/p>\n\n

      The addition of Liraglutide and sublingual\/buccal routes of administration for the GLP1s reflects Hydreight’s mission<\/strong> to expand access<\/span> <\/strong>to premium<\/span> wellness <\/strong>and weight management therapies<\/strong> through a convenient<\/span>, compliant<\/span>, and nationwide<\/span> telehealth network<\/strong>. The VSDHOne platform simplifies<\/span><\/strong> the entire<\/span> patient journey<\/strong> from telehealth consult<\/strong> to prescription<\/strong> and delivery<\/strong><\/span>, while offering<\/span> medical professionals<\/strong> the flexibility<\/strong><\/span> to provide<\/span> treatments<\/strong> at scale<\/strong><\/span>.<\/span><\/p>\n\n

      Liraglutide<\/strong> will be available to all<\/strong><\/span> eligible<\/span> VSDHOne customers<\/strong>, ensuring <\/strong><\/span>widespread<\/strong><\/span> access<\/strong><\/span> to these innovative<\/span> wellness treatments<\/strong>.<\/span><\/p>\n\n

      On behalf of the Board of Directors<\/span><\/p>\n\n

      Shane Madden
      \nDirector and Chief Executive Officer
      \nHydreight Technologies Inc.<\/span><\/p>\n\n

      Hydreight Technologies Inc Ranked Number 56 Fastest-Growing<\/span> Company in North America on the 2024 Deloitte Technology Fast 500™<\/em><\/strong><\/span><\/p>\n\n

      Hydreight Technologies Recognized<\/span> by the Financial Times Ranking 13th<\/span> as One of the Americas’ Fastest Growing<\/span> Companies in 2025<\/em><\/strong><\/span><\/p>\n\n

      Contact
      \nEmail: ir@hydreight.com; Telephone: 1 (702) 970-8112<\/span><\/p>\n\n

      About Hydreight Technologies Inc.<\/strong>
      \nHydreight Technologies Inc is building one of the largest mobile clinic network in the United States. Its proprietary, fully integrated platform hosts a network of over 2500 nurses, over 100 doctors and a pharmacy network across 50 states. The platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking, and managing patient data, which enables licensed healthcare professionals to provide services directly to patients at home, office or hotel. Hydreight is bridging the gap between provider compliance and patient convenience, empowering nurses, med spa technicians, and other licensed healthcare professionals. The Hydreight platform allows healthcare professionals to deliver services independently, on their own terms, or to add mobile services to existing location-based operations. Hydreight has a 503B pharmacy network servicing all 50 states and is closely affiliated with a U.S. certified e-script and telemedicine provider network.<\/span><\/p>\n\n

      This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.<\/span><\/p>\n\n

      About VSDHOne – Direct to Consumer Platform<\/strong>
      \nDeveloped in partnership with Victory Square Technologies (CSE: VST) (OTC: VSQTF) (FWB: 6F6), Hydreight Technologies launched the VSDHOne (Read as VSDH-One) platform. VSDHOne simplifies the entry challenges for companies and medi-spa businesses to enter the online healthcare space compliantly. This platform will help all businesses to launch a direct-to-consumer healthcare brand in a matter of days in all 50 states. Compliant offerings include: GLP-1s (semaglutide, tirzepatide, liraglutide), peptides, personalized healthcare treatments, sermorelin, testosterone replacement therapy (“TRT”), hair loss, skincare, sexual health and more. Hydreight invested in technology, legal and infrastructure to launch this platform. The VSDHOne platform offers a complete, end-to-end solution for businesses looking to launch direct-to-consumer healthcare brands. From compliance and telemedicine technology to nationwide doctor and pharmacy networks, VSDHOne provides all the tools needed for a seamless entry into the online healthcare space. The platform is designed to significantly reduce the time and costs associated with launching such services, making it possible for businesses to go live in days instead of months.<\/span><\/p>\n\n

      Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. NIA has received compensation from NURS of US$30,000 cash for a three-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.<\/em><\/span><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

      Huge news out from Hydreight Technologies (TSXV: NURS). This is a rapidly growing future household name company that is set to become a leader of America’s booming telehealth technology space across all 50 states! RFK Jr. told NIA’s President at Trump’s Inauguration that he is extremely bullish on telehealth technology and believes it will play the most important […]<\/p>\n","protected":false},"author":1,"featured_media":67,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[10,8],"class_list":["post-409","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-announcement","tag-nurs","tag-technology"],"_links":{"self":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/comments?post=409"}],"version-history":[{"count":1,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/409\/revisions"}],"predecessor-version":[{"id":410,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/409\/revisions\/410"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/media\/67"}],"wp:attachment":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/media?parent=409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/categories?post=409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/tags?post=409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}